Telogen effluvium: how stress and illness shift hair into shedding

The hair cycle and what "telogen" means

Every scalp follicle moves through a repeating cycle rather than growing continuously. The active growth phase is called anagen and, on a healthy scalp, it lasts for years; most follicles are in anagen at any given moment. A short transition phase, catagen, follows over a few weeks, and then the follicle enters telogen, a resting phase that typically lasts a couple of months. At the end of telogen the old hair is released, an event sometimes called exogen, and a new anagen hair begins to grow in its place.

Under normal conditions these cycles are staggered, or asynchronous, across the scalp. Because each follicle keeps its own schedule, only a small share of hairs sits in the resting phase at any time, and the everyday shedding that results is spread out and largely unnoticed. Descriptions of a typical scalp put the resting fraction in the rough range of a tenth of follicles, with day-to-day loss on the order of dozens of hairs.

Telogen effluvium is the name given to a pattern in which an unusually large number of follicles enter telogen at roughly the same time. "Effluvium" simply refers to an outflow or shedding. The defining feature is not damage to the follicles themselves but a shift in their timing, which is why the process is generally described as diffuse and temporary rather than scarring.

How a physiological shock is understood to synchronize follicles

The central idea behind telogen effluvium is synchronization. When the body experiences a significant stressor, a large group of follicles that would otherwise have stayed in anagen for months or years is understood to exit the growth phase prematurely and move into telogen together. Instead of shedding on their own independent schedules, these follicles become time-locked, and the loss that follows is concentrated rather than dispersed.

Researchers study several candidate signals for how this shift is triggered. The stress-response system, including the hypothalamic-pituitary-adrenal axis and its downstream messengers such as cortisol, is one pathway described in the literature. Neuropeptides released around the follicle, including substance P, and local inflammatory signaling have also been examined as mediators that may nudge follicles out of anagen. In these models the follicle is not destroyed; its clock is reset toward rest.

A well-recognized example of timing-driven shedding is the postpartum period. During pregnancy, elevated hormone levels are understood to prolong anagen, so fewer follicles than usual cycle into rest. After delivery, as those levels fall, many of the follicles that were held in growth transition into telogen over a short window, which can produce a synchronized shed some weeks to months later. The mechanism is one of coordinated timing, not follicle loss.

Why the shedding appears months after the trigger

One of the most distinctive features of telogen effluvium is a delay between the event and the visible shedding. Because a follicle that shifts into telogen still has to move through the full resting phase before the old hair is released, the outflow typically becomes noticeable roughly two to three months after the underlying shock. By the time a person sees more hairs on the pillow or in the shower, the triggering event may feel like it is already in the past.

This lag helps explain why the pattern is often discussed in the context of a preceding stressor. Events that are commonly described as potential triggers in the medical literature include:

• High fever or acute illness
• Major surgery or physical trauma
• Childbirth
• Rapid or substantial changes in weight or nutrition
• Shifts in thyroid signaling
• Periods of severe psychological stress

Certain medications are also studied as possible triggers. In each case, the proposed mechanism is a temporary push of follicles toward the resting phase rather than a permanent change.

Natural history is usually described as self-limited in the acute form: once the trigger resolves, the synchronized follicles complete telogen, shed, and re-enter anagen, and the wave of shedding tapers over a period of months. A longer-lasting or fluctuating pattern is sometimes distinguished separately as chronic telogen effluvium. How any individual case behaves, and what may be driving it, is a clinical assessment for a licensed provider rather than something an article can determine.

How this differs from pattern hair loss

Telogen effluvium is mechanistically distinct from androgenetic alopecia, the pattern hair loss driven by follicle sensitivity to the androgen DHT. In pattern loss, susceptible follicles progressively miniaturize over many cycles, producing finer, shorter hairs in characteristic regions such as the crown or hairline. In telogen effluvium the follicles are not miniaturizing; a normal-sized cohort has simply been shifted into rest at once, which is why the shedding is typically described as diffuse and spread across the whole scalp rather than concentrated in a pattern.

The two processes can be discussed together because they can coexist, and a synchronized shed can sometimes make an underlying pattern more apparent. They are nonetheless different phenomena: one is about the timing of the hair cycle, the other about a hormone-driven change in follicle size over time. Distinguishing them, often with a clinical history and examination, is part of why hair shedding is evaluated individually rather than assumed to have a single cause.

Because the mechanisms differ, the science that is studied around each also differs. Ingredients researched in the context of pattern hair loss, such as agents that act on 5-alpha-reductase and DHT or that act directly on the follicle, are described in relation to that specific biology. This article does not assert that any product changes the course of telogen effluvium; the intent here is only to explain how the resting-phase shift is understood to work.

Educational scope and how provider review works

This article is educational and is not medical advice. It describes how a physiological shock is understood to synchronize follicles into the resting phase; it does not diagnose the cause of any person's shedding, recommend a product, or provide dosing. Diffuse hair shedding can have many overlapping contributors, and sorting them out is a clinical task. A licensed provider, working from an individual's history and evaluation, makes every decision about assessment and any treatment.

Where compounded medications are discussed anywhere on this site, it is worth noting that compounded preparations are not FDA-approved products, and statements about them have not been evaluated by the U.S. Food and Drug Administration. Any prescription product is dispensed only after independent clinical review, not on request.

On OpenDoseRx, that review is built into the process. You select a product and complete a medical intake with your health history, and that intake is routed to an independent, licensed U.S. provider. If the provider determines a prescription is appropriate, it is sent to a licensed U.S. pharmacy for fulfillment; if the request is declined, you are not charged for the medication. Nothing here replaces a conversation with your own provider.